HRP20241376T1 - 3beta-(benziloksi)-17alfa-metil-pregn-5-en-20-on za uporabu u liječenju kognitivnih poremećaja - Google Patents

3beta-(benziloksi)-17alfa-metil-pregn-5-en-20-on za uporabu u liječenju kognitivnih poremećaja Download PDF

Info

Publication number
HRP20241376T1
HRP20241376T1 HRP20241376TT HRP20241376T HRP20241376T1 HR P20241376 T1 HRP20241376 T1 HR P20241376T1 HR P20241376T T HRP20241376T T HR P20241376TT HR P20241376 T HRP20241376 T HR P20241376T HR P20241376 T1 HRP20241376 T1 HR P20241376T1
Authority
HR
Croatia
Prior art keywords
compound
use according
treatment
syndrome
disorder
Prior art date
Application number
HRP20241376TT
Other languages
English (en)
Croatian (hr)
Inventor
Pier-Vincenzo Piazza
Sandy FABRE
Stéphanie MONLEZUN
Mathilde METNA
Monique VALLEE
Jean-Michel REVEST
Daniela COTA
Giovanni Marsicano
Aline MARIGHETTO
Andrés OZAITA
Rafael MALDONADO
Original Assignee
Aelis Farma
Universite de Bordeaux
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aelis Farma, Universite de Bordeaux, Institut National De La Sante Et De La Recherche Medicale (Inserm) filed Critical Aelis Farma
Publication of HRP20241376T1 publication Critical patent/HRP20241376T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20241376TT 2018-12-18 2019-12-18 3beta-(benziloksi)-17alfa-metil-pregn-5-en-20-on za uporabu u liječenju kognitivnih poremećaja HRP20241376T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306716.4A EP3669876A1 (en) 2018-12-18 2018-12-18 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
EP19831675.4A EP3897655B1 (en) 2018-12-18 2019-12-18 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
PCT/EP2019/085927 WO2020127468A1 (en) 2018-12-18 2019-12-18 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS

Publications (1)

Publication Number Publication Date
HRP20241376T1 true HRP20241376T1 (hr) 2024-12-20

Family

ID=65278139

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241376TT HRP20241376T1 (hr) 2018-12-18 2019-12-18 3beta-(benziloksi)-17alfa-metil-pregn-5-en-20-on za uporabu u liječenju kognitivnih poremećaja

Country Status (26)

Country Link
US (1) US12583884B2 (cg-RX-API-DMAC7.html)
EP (2) EP3669876A1 (cg-RX-API-DMAC7.html)
JP (1) JP7515480B2 (cg-RX-API-DMAC7.html)
KR (1) KR102845328B1 (cg-RX-API-DMAC7.html)
CN (1) CN113260366B (cg-RX-API-DMAC7.html)
AU (1) AU2019409912B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011654A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118210C (cg-RX-API-DMAC7.html)
CL (1) CL2021001458A1 (cg-RX-API-DMAC7.html)
DK (1) DK3897655T3 (cg-RX-API-DMAC7.html)
ES (1) ES2987823T3 (cg-RX-API-DMAC7.html)
FI (1) FI3897655T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241376T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068626T2 (cg-RX-API-DMAC7.html)
IL (1) IL284032B2 (cg-RX-API-DMAC7.html)
LT (1) LT3897655T (cg-RX-API-DMAC7.html)
MA (1) MA54518B1 (cg-RX-API-DMAC7.html)
MD (1) MD3897655T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006904A (cg-RX-API-DMAC7.html)
PL (1) PL3897655T3 (cg-RX-API-DMAC7.html)
PT (1) PT3897655T (cg-RX-API-DMAC7.html)
RS (1) RS66013B1 (cg-RX-API-DMAC7.html)
SI (1) SI3897655T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400425T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020127468A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103284B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007382A (es) 2018-12-18 2021-07-15 Merck Sharp & Dohme Llc Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih.
WO2024085245A1 (ja) 2022-10-21 2024-04-25 国立大学法人高知大学 術後せん妄の抑制薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004234125A1 (en) 2003-05-01 2004-11-11 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders
ATE496894T1 (de) 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
CN101790521A (zh) 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
CN106983754A (zh) 2011-05-20 2017-07-28 国家医疗保健研究所 Cb1受体拮抗剂
RU2667065C2 (ru) * 2012-11-28 2018-09-14 Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) Производные прегненолона
LT2976074T (lt) * 2013-03-19 2020-03-25 Universitat Pompeu-Fabra Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis
IL276697B2 (en) 2018-02-20 2024-08-01 Aelis Farma 3beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders

Also Published As

Publication number Publication date
HUE068626T2 (hu) 2025-01-28
DK3897655T3 (da) 2024-09-23
IL284032A (en) 2021-08-31
CN113260366B (zh) 2024-03-08
MA54518B1 (fr) 2024-11-29
AU2019409912A1 (en) 2021-05-27
JP7515480B2 (ja) 2024-07-12
PL3897655T3 (pl) 2025-01-13
KR102845328B1 (ko) 2025-08-12
IL284032B1 (en) 2025-01-01
EP3897655B1 (en) 2024-07-17
MD3897655T2 (ro) 2024-12-31
PT3897655T (pt) 2024-10-14
AU2019409912A8 (en) 2021-06-17
KR20210124962A (ko) 2021-10-15
US20220017562A1 (en) 2022-01-20
SI3897655T1 (sl) 2025-04-30
RS66013B1 (sr) 2024-10-31
BR112021011654A2 (pt) 2021-09-08
WO2020127468A1 (en) 2020-06-25
CL2021001458A1 (es) 2022-01-21
EP3897655A1 (en) 2021-10-27
CA3118210A1 (en) 2020-06-25
MA54518A (fr) 2022-02-16
US12583884B2 (en) 2026-03-24
CA3118210C (en) 2024-05-21
SMT202400425T1 (it) 2024-11-15
CN113260366A (zh) 2021-08-13
JP2022515373A (ja) 2022-02-18
ES2987823T3 (es) 2024-11-18
FI3897655T3 (fi) 2024-09-17
ZA202103284B (en) 2024-09-25
LT3897655T (lt) 2024-10-10
AU2019409912B2 (en) 2025-02-20
MX2021006904A (es) 2021-09-30
EP3669876A1 (en) 2020-06-24
IL284032B2 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
JOP20200160B1 (ar) محاليل معلقة مائية للمركبات المسمى تي ام سي 278
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
JP2019529541A5 (cg-RX-API-DMAC7.html)
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
EA201100305A1 (ru) Лечение респираторных заболеваний
HRP20191919T1 (hr) Donori nitroksila sa poboljšanim terapijskim indeksom
JP2012180381A5 (cg-RX-API-DMAC7.html)
FI3577124T3 (fi) Nukleotidihemisulfaattisuola hepatiitti C -viruksen hoitoon
JP2018535989A5 (cg-RX-API-DMAC7.html)
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
UA114405C2 (uk) Феніл-3-азабіцикло[3.1.0]гекс-3-илметанони та їх застосування як лікарського засобу
WO2008155357A3 (en) Use of dopamine stabilizers
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
JP2014065696A5 (cg-RX-API-DMAC7.html)
CY1118229T1 (el) Ενωση κινολονης και φαρμακευτικη συνθεση
JP2013533269A5 (cg-RX-API-DMAC7.html)
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
FI3044229T3 (fi) Peptidejä käytettäväksi suun limakalvotulehduksen hoidossa
AR120174A1 (es) Inhibidores del factor d del complemento para administración oral
JP2016537338A5 (cg-RX-API-DMAC7.html)
RU2015134421A (ru) Применение левоцетиризина и монтелукаста при лечении травматических повреждений
FI3897655T3 (fi) 3 -(bentsyylioksi)-17 -metyylipregn-5-en-20-oni käytettäväksi kognitiivisten häiriöiden hoitamisessa
JP2014148552A5 (cg-RX-API-DMAC7.html)
MX2021008966A (es) Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular.